Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AkaRx Inc., MGI deal

AkaRx retains rights to commercialize the compounds and is eligible for $45 million in upfront

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE